ZincFive Launches Next-Generation BMS, Setting a New Standard for Nickel-Zinc Battery Management
9.9.2026 14:05:00 CEST | Business Wire | Press Release
ZincFive®, the leader in nickel-zinc (NiZn) battery-based solutions for immediate power applications, today launched the ZincFive BMS, a next-generation battery management system purpose-built for its NiZn chemistry, designed and assembled in the U.S.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260909653032/en/
The ZincFive BMS ships standard with every ZincFive BC Series UPS Battery Cabinets, serving as the primary interface for data center operators, UPS OEM partners, and system integrators to monitor and manage ZincFive’s technology.
Built on years of experience managing NiZn in real-world data center environments, ZincFive engineered the BMS around the unique characteristics of its NiZn chemistry, rather than adapting a platform designed for lithium-ion or lead-acid batteries. The result is a streamlined two-tier hardware architecture, consisting of the ZincFive Controller and ZincFive Tray Monitor, that delivers high-resolution telemetry across the entire battery cabinet while simplifying system design.
The streamlined architecture simplifies cabinet wiring, eliminates the need for third-party unmanaged network switches, and reduces installation time, infrastructure complexity, and hardware costs. Cabinets daisy-chain via dual Ethernet ports, while the Tray Monitor measures individual battery voltage and temperature via isoSPI protocol, eliminating an additional data aggregation layer and simplifying integration with the data center’s building management system.
The ZincFive BMS is assembled in the U.S., with hardware, software and firmware developed entirely at ZincFive’s headquarters in the U.S. This integrated approach gives ZincFive greater control over the platform, from deployment and upgrades to ongoing innovation and customer-driven enhancements.
As AI workloads continue to reshape data center power requirements, AI pulse intelligence is enabled through the ZincFive BMS in BC 2 AI UPS Battery Cabinets, allowing the system to respond to the high-frequency power pulses associated with AI training and inference workloads.
The ZincFive BMS also incorporates advanced cybersecurity into battery management. Encryption, authentication, hardened communications, and comprehensive access controls are built in from the ground up, helping meet increasingly stringent operational technology (OT) security requirements while providing audit-ready visibility.
A redesigned interface gives operators fleet-wide visibility and control, with access to key system attributes such as state of charge and voltage, time-series data, advanced alarms and alerts, and a comprehensive user and permissions hierarchy for multi-site deployments. Operators can also remotely configure systems and deploy firmware updates. With the hardware, software, and firmware designed and supported in-house by ZincFive, improvements and customer-requested enhancements can be delivered directly without reliance on third-party vendors.
“The ZincFive BMS reflects everything we’ve learned from managing and deploying nickel-zinc batteries at scale,” said Tod Higinbotham, CEO of ZincFive. “By bringing development in-house and assembling the BMS in the U.S., we have greater control over the platform and how it evolves. Purpose-built for our battery chemistry, it delivers greater visibility, stronger cybersecurity, and a simpler deployment experience, while giving us the ability to continuously evolve the platform alongside our customers’ needs. As AI reshapes data center power requirements, this level of intelligence and control becomes increasingly critical.”
With more than 2 gigawatts of NiZn power delivered or contracted globally, ZincFive brings years of real-world deployment experience and engineering expertise to the ZincFive BMS. Purpose-built for ZincFive NiZn and standard with every ZincFive BC Series UPS Battery Cabinets, the BMS strengthens a technology platform designed to deliver high-performance immediate power with superior safety and sustainability for mission-critical infrastructure worldwide.
About ZincFive, Inc.
ZincFive is the leader in immediate power solutions for mission-critical infrastructure based on nickel-zinc battery technology. The company’s extensively patented nickel-zinc technology delivers high-power, safe, reliable, and sustainable energy storage solutions engineered for the demands of modern data centers, industrial operations, and AI-era infrastructure. ZincFive’s systems harness The Power of Good Chemistry® to help customers power what’s next without tradeoffs. Headquartered in Oregon, USA, ZincFive serves customers worldwide. For more information, visit www.zincfive.com.
ZincFive and The Power of Good Chemistry are registered trademarks of ZincFive, Inc. and the ZincFive logo is a trademark of ZincFive, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260909653032/en/
Contacts
Media Contact:
Jake Curtachio
iMiller Public Relations for ZincFive
Tel: +1.914.315.6424
Email: media@zincfive.com
Follow ZincFive:LinkedIn -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.linkedin.c
om%2Fcompany%2Fzincfive-inc%2F&esheet=54600441&newsitemid=20260909653032&lan=en-
US&anchor=LinkedIn&index=6&md5=75064f464be8190e0439e58ab5c9d88f | YouTube -
https://cts.businesswire.com/ct/CT?id=smartlink&url=https%3A%2F%2Fwww.youtube.co
m%2Fchannel%2FUCfbwY63HiTbGZHMIDNwBN4Q&esheet=54600441&newsitemid=20260909653032
&lan=en-US&anchor=YouTube&index=7&md5=ac55dc905564637fe1506e56793f04f4
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 10:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom